Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo(r)|Forsteo(r), to the EU, MENA, and ROW

Source :: Plus Company Updates. March 1, 2019
Publication Year :: 2019
Abstract: California: Pfenex, Inc. has issued the following news release: Pfenex Inc. (NYSE American: PFNX) and Alvogen Ltd. today announced entering into agreements expanding their collaboration to develop and commercialize Pfenex's [...]

Subjects :: Eli Lilly and Co. -- Research agreements
Pharmaceutical industry -- Research agreements -- Health aspects
Diphtheria toxoid -- Health aspects
Business logistics -- Health aspects
Backup software
General interest
News, opinion and commentary
Forteo (Medication) -- Health aspects

Tools